NR2F1 and hepatocellular carcinoma: Based on the report from Huang’s group, NR2F1-AS1, the expression of which in oxaliplatin-resistant tissues was augmented, could target ABCC1 by sponging miR-363 and confer resistance to hepatocellular carcinoma [53].